Special Issue "Recombinant Glycoproteins"
A special issue of Bioengineering (ISSN 2306-5354).
Deadline for manuscript submissions: closed (28 February 2017).
Interests: biochemistry of glycans; chemical biology; glycan engineering; glycan analysis; glycobiotechnology; sialic acids; therapeutic glycoproteins
Interests: bioprocess engineering; carbohydrate interactions; cell line engineering; glycan engineering; glycobiology; intracellular N-glycan processing; sugar nucleotide metabolism; therapeutic glycoproteins
Recombinant glycoproteins have emerged as a prominent class of pharmaceutically active molecules with an ever increasing number of new therapeutic and preventive indications. Therapeutic antibodies, hormones, cytokines and glycosylated vaccines are produced by mammalian cell culture, a process depending on living cells that is notoriously difficult to control and validate and also inherently prone to cell line and process induced product variations. Of all posttranslational product modifications, glycosylation is the most complex and is well known for its contribution to overall product microheterogeneity. Changes in the glycosylation profile of a product have a prominent impact on drug safety, pharmacodynamics and pharmacokinetics. Therefore, it comes as no surprise that the entire field of glycobiology has gained so much attention from industry.
The current Special Issue emphasizes technical advances in this important field of recombinant glycoproteins, including advances in the field of glycoprotein engineering, process impact on glycoprotein integrity, in-process glycan analysis as well as discoveries pertaining to glycan functional activities. This may include engineering of the protein backbone as well as the attached glycans of a recombinant glycoprotein. Creation of novel recombinant glycoproteins with improved or completely new features, as well as studies aimed at achieving chemically homogenous glycosylation, are also of interest.
We look forward to receiving your contributions to these state-of-the-art issues.
Prof. Dr. Stephan Hinderlich
Prof. Dr. Hans Henning von Horsten
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Glycan engineering
- Cell line engineering
- Therapeutic glycoproteins
- Recombinant monoclonal antibodies
- Antibody–drug conjugates